Annovis Bio Inc. (ANVS): Price and Financial Metrics
GET POWR RATINGS... FREE!
ANVS Stock Price Chart Interactive Chart >
ANVS Price/Volume Stats
|Current price||$12.07||52-week high||$132.00|
|Prev. close||$11.34||52-week low||$8.39|
|Day high||$12.20||Avg. volume||56,232|
|50-day MA||$10.44||Dividend yield||N/A|
|200-day MA||$18.01||Market Cap||98.54M|
Annovis Bio Inc. (ANVS) Company Bio
Annovis Bio, Inc. develops drugs for Alzheimer's and Parkinson's diseases and other neurodegenerative disorders. It offers posiphen compound for mild cognitive impairment and early stage Alzheimer's disease and bisnorcymserine compound that inhibits amyloid formation and prevents the progression of the Alzheimer's disease. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.
Most Popular Stories View All
ANVS Latest News Stream
|Loading, please wait...|
ANVS Latest Social Stream
View Full ANVS Social Stream
Latest ANVS News From Around the Web
Below are the latest news stories about Annovis Bio Inc that investors may wish to consider to help them evaluate ANVS as an investment opportunity.
News out of Greater Philadelphia's life sciences industry this week includes a pharmaceutical packaging partnership, a cell and gene therapy distribution alliance, a lease deal, a gene therapy candidate, and more. Here's the roundup: West Pharmaceutical Services The Exton-based designer and manufacturer of injectable pharmaceutical packaging and delivery systems entered into an exclusive supply and technology agreement with specialty glass and materials maker Corning Inc. According to the companies, the deal will facilitate a multimillion-dollar capital and research and development investment to expand work on Corning's Valor glass technology and to produce advanced injectable drug packaging and delivery systems for the pharmaceutical industry.
Annovis Bio Inc (NYSE: ANVS) has completed a Type B meeting with the FDA regarding its planned Phase 3 studies of Buntanetap for the treatment of Parkinson's Disease (PD) as an offshoot of the Company's clinical program in Alzheimer's Disease (AD). Following the Company's submission of Phase 2 data and the chronic toxicology data in animals, the Company requested directions to further develop Buntanetap in PD. The FDA guided initiating the Phase 3 clinical studies of Buntanetap for PD parallel w
Annovis Bio Announces Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson's Disease
FDA gives guidance for two Phase 3 clinical trials of Buntanetap in Parkinson's Disease Berwyn, Pennsylvania--(Newsfile Corp. - January 25, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced that the company held a successful Type B meeting with the U.S. Food and Drug Administration (FDA) with regard to the Company's planned Phase 3 clinical studies of Buntanetap for the treatment of P
As Annovis Bio, Inc.'s market cap (NYSE:ANVS) drops to US$117m, insiders might be questioning their decision to buy earlier this year
The recent price decline of 18% in Annovis Bio, Inc.'s ( NYSE:ANVS ) stock may have disappointed insiders who bought...
Company Appoints Eve Damiano, MS, RAC, as Senior Vice President of Regulatory OperationsCompany Promotes Cheng Fang, Ph.D., to Senior Vice President of Research & DevelopmentBerwyn, Pennsylvania--(Newsfile Corp. - January 10, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced the appointment of Eve Damiano, MS, RAC, as its new Senior Vice President of Regulatory Operations, and the pro
ANVS Price Returns